Regulation of Outflow Facility by Gene Transfer

Univ Of North Carolina Chapel Hill, Chapel Hill NC

Investigators

Linked publications, trials & patents

Abstract

DESCRIPTION (provided by applicant): The general hypothesis of this ongoing project has been that modulating gene expression of the outflow pathway cells by gene transfer would control elevated intraocular pressure (IOP) in a more specific, regulated and prolonged manner than current conventional drugs. During these past cycles we have accumulated extensive knowledge and expertise about gene transfer to the trabecular meshwork (TM). We have identified safe viral vectors and candidate genes, and we developed the first inducible vectors expressing the therapeutic product only when is needed. Specifically, we proved that one of our viruses carrying a steroid-inducible human metallopeptidase I (MMP1) (AdhGRE.MMP1) overexpressed the enzyme in the presence of steroids and returned its expression to baseline in their absence. Intracameral injection of this vector to sheep lowered and prevented steroid-induced hypertension in this large animal model, while administration of the mutant MMP1 (AdhGRE.mMMP1) did not. Because the use of glucocorticoids (GCs) is so essential in today's ophthalmology practice and because their side effect on IOP is so damaging, our goal for this grant period is to build on our findings and develop a clinical gene therapy treatment of steroid-induced hypertension by the end of this project. We intend to carry out the project in three consecutive phases which correlate with specific aims. On the first phase (SA#1), we will concentrate on the comprehensive optimization and development of the final targeting vector. On the second phase (SA#2) we will use the large animal model (sheep) for measuring the vector's efficacy in counteracting IOP elevation, expression during a steroid on/off switch, routes of administration and determination of the clinical relevant dose (CRD). On the third phase (SA#3) we will assess all major toxicity parameters, including clinical outcomes, immune responses, and biodistribution according to FDA guidelines for gene therapy viral vectors. We expect that completion of this project will provide all needed preclinical efficacy and safety requirements for setting up a Phase I clinical trial for the treatment of steroid glaucoma patients